Roche Holding AG (RHHBY.PK) said its first-quarter group sales rose 2% at constant exchange rates to 11.03 billion Swiss francs from a year ago. Excluding Tamiflu, sales growth is 3%. Sales were down 1% in Swiss francs, while it was up 1% in US dollars.
Roche also confirmed its full-year outlook for 2012. Barring unforeseen events, Roche still expects low to mid-single-digit sales growth at constant exchange rates for the Group and the Pharmaceuticals Division in 2012.
Despite a challenging market environment, based on the expected sales growth and continued efficiency improvements, Roche continues to aim for a high single-digit increase in Core Earnings per Share at constant exchange rates.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org